Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Negrier

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinomaC Lasset, Y Merrouche, S Negrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1992
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2P A Palmer, J Vinke, T Philip, et al.
Journal De Chirurgie|June 1, 1992
[Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience]S Negrier, A Mercatello, B Coronel, et al.
Pediatric Hematology and Oncology|January 1, 1990
Autologous bone marrow transplantation in pediatric solid tumorsI Yaniv, E Bouffet, C Irle, et al.
The Journal of Urology|May 19, 2009
Sequential sorafenib and sunitinib for renal cell carcinomaM P Sablin, S Negrier, A Ravaud, et al.
Molecular Biotherapy|March 1, 1990
Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture techniqueM C Favrot, C Coze, V Combaret, et al.
Cancer Treatment Reviews|June 1, 1989
A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 casesM Favrot, D Floret, J Michon, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
Medical and Pediatric Oncology|January 1, 1994
The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary reportC Carrie, N Breteau, S Negrier, et al.
Cancer Research|April 15, 1990
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factorJ Y Blay, M C Favrot, S Negrier, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinomaC Lasset, Y Merrouche, S Negrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1992
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2P A Palmer, J Vinke, T Philip, et al.
Journal De Chirurgie|June 1, 1992
[Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience]S Negrier, A Mercatello, B Coronel, et al.
Pediatric Hematology and Oncology|January 1, 1990
Autologous bone marrow transplantation in pediatric solid tumorsI Yaniv, E Bouffet, C Irle, et al.
The Journal of Urology|May 19, 2009
Sequential sorafenib and sunitinib for renal cell carcinomaM P Sablin, S Negrier, A Ravaud, et al.
Molecular Biotherapy|March 1, 1990
Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture techniqueM C Favrot, C Coze, V Combaret, et al.
Cancer Treatment Reviews|June 1, 1989
A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 casesM Favrot, D Floret, J Michon, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
Medical and Pediatric Oncology|January 1, 1994
The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary reportC Carrie, N Breteau, S Negrier, et al.
Cancer Research|April 15, 1990
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factorJ Y Blay, M C Favrot, S Negrier, et al.
Pageof 5